Loading...
Thumbnail Image
Publication

Mechanistic and Cytotoxicity Studies of Group IV b-Diketonate Complexes

Lord, Rianne M.
Mannion, J.J.
Hebden, A.J.
Nako, A.E.
Crossley, B.D.
McMullon, M.W.
Janeway, F.D.
Phillips, Roger M.
McGowan, P.C.
Publication Date
2014-06
End of Embargo
Supervisor
Rights
Peer-Reviewed
Yes
Open Access status
closedAccess
Accepted for publication
Institution
Department
Awarded
Embargo end date
Additional title
Abstract
Group IV metal complexes have previously shown promise as novel anticancer agents. Here, we discuss the mechanistic and cytotoxic nature of a series of group IV b-diketonate coordination complexes. Clear evidence that the ligands are exchangeable on the metal centre and that the b-diketonate ligands can act as potential drug delivery vehicles of the group IV metal ions was obtained. When evaluated for the cytotoxicity against human colon adenocarcinoma (HT-29) and human breast adenocarcinoma (MCF-7) cell lines, a general trend of decreasing potency down the group IV metals was observed. The most promising results obtained were for the hafnium complexes, with the tris diphenyl b-diketonate hafnium complex exhibiting IC50 values of 4.9 0.9 mm and 3.2 0.3 mm against HT-29 and MCF-7, respectively, which are comparable with the activity of cisplatin against the same cell lines. This tri b-diketonate hafnium complex is the first to show potent in vitro cytotoxic activity. The results reported show that ligand design has a significant effect on the cytotoxic potential of the complexes, and that these group IV complexes warrant further evaluation as novel metal-containing anticancer agents.
Version
No full-text in the repository
Citation
Lord RM, Mannion JJ, Hebden AJ, Nako AE, Crossley BD, McMullon MW, Janeway FD, Phillips RM and McGowan PC (2014) Mechanistic and Cytotoxicity Studies of Group IV b-Diketonate Complexes. ChemMedChem. 9(6): 1136–1139.
Link to publisher’s version
Link to published version
Type
Article
Qualification name
Notes